-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 4, Pfizer filed a CDE application in China for the listing of Essaconazole sulphuric acid capsules and injection aesulphate.
, a new antifellar drug developed by Basilea Pharmaceutica, was approved by the FDA in March 2015 under the name Crisemba.
Cresemba has been approved in more than 40 countries and territories around the world, with invasive creatosis and hairy mold, both of which can be life-threatening in patients with cancer or other immunodeficiability.
December 2017, Pfizer reached an agreement with Basilea Pharmaceutica to obtain exclusive development and sales rights for Asaconzo in several countries in China and the Asia Pacific region.
.